

Special Issue

Pneumococcal Conjugate Vaccines and Prevention of Non-invasive and Invasive Pneumococcal Diseases

Message from the Guest Editor

While PCVs has shown a tremendous efficacy against some serotypes, the vaccine responses and protection against serotype 3 remain low and therefore, a formidable challenge, despite the immense overall efficacy of PCVs. Despite the continued success of PCV immunization, nonvaccine colonization and disease-causing serotypes have emerged. However, the current cost of PCVs makes them less likely to be used extensively in developing countries where the need is the highest. This Special Issue will focus on pneumococcal anticapsular antibody responses and comprehensive analysis of serotype-specific efficacy of PCV formulations across geographies. The issue will focus on the systematic reduction of non-invasive (sinusitis, otitis media, pneumonia) and invasive serotypes after the administration of PCVs in at-risk human populations, i.e., children, the elderly and immunocompromised. The issue will also focus on nonvaccine emergent serotypes and extension of the valency of new PCVs to address emergent serotypes, as well as newer noncapsular vaccine approaches against pneumococcal diseases.

Guest Editor

Dr. Nadeem Khan

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, ND, USA

Deadline for manuscript submissions

closed (31 January 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/41396

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).